Vivos Therapeutics Reports Q2 2026 Earnings Amid Strategic Collaborations
Event summary
- Vivos Therapeutics will release its Q2 2026 financial results on August 14, 2026.
- Conference call scheduled for 5:00 PM Eastern Time to discuss strategic collaborations and their impact on revenue growth and cash burn.
- Company focuses on innovative diagnostic and treatment modalities for obstructive sleep apnea (OSA) and other sleep-related breathing disorders.
- Vivos' CARE devices are FDA-cleared for treating severe OSA in adults and moderate-to-severe OSA in children.
The big picture
Vivos Therapeutics is positioning itself as a leader in non-invasive treatments for OSA, leveraging strategic collaborations to drive growth. The company's FDA-cleared CARE devices address a significant unmet need in the sleep health market, which affects over 1 billion adults worldwide. However, the competitive landscape and regulatory environment pose challenges that could impact its long-term strategy.
What we're watching
- Revenue Growth
- How strategic collaborations will impact near-term revenue growth.
- Cash Burn
- Whether the company can manage cash burn effectively amid strategic initiatives.
- Regulatory Compliance
- The pace at which Vivos can navigate regulatory scrutiny in the sleep apnea treatment sector.
Related topics